Influence of a ketogenic diet, fish-oil, and calorie restriction on plasma metabolites and lipids in C57BL/6J mice

Nutrition and Metabolism

Volumn 11, Issue 1, 2014, Pages

  Meidenbauer, Joshua J ^a   Ta, Nathan ^a   Seyfried, Thomas N ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

Calorie restriction; Glucose; Ketogenic diet; Ketones; Omega 3 fatty acids

Indexed keywords

3 HYDROXYBUTYRIC ACID; ADIPONECTIN; CHOLESTEROL; CHOLESTEROL ESTER; FATTY ACID; FISH OIL; GLUCOSE; INSULIN; LIPID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; SPHINGOMYELIN; TRIACYLGLYCEROL;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CALORIC INTAKE; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; FATTY ACID BLOOD LEVEL; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KETOGENIC DIET; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

MUS; RODENTIA;

EID: 84902257983     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-11-23     Document Type: Article

References (111)

1. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Stafstrom CE, Rho JM, Front Pharmacol 2012 3 59 22509165
2. Dietary manipulation and caloric restriction in the development of mouse models relevant to neurological diseases. Schroeder JE, Richardson JC, Virley DJ, Biochim Biophys Acta 1802 2010 840 846
3. The ketogenic diet: uses in epilepsy and other neurologic illnesses. Baranano KW, Hartman AL, Curr Treat Options Neurol 2008 10 410 419 10.1007/s11940-008-0043-8 18990309
4. World Health Organization, Diet, Nutrition, and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation Geneva: World Health Organization 2003
5. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Kashiwaya Y, Bergman C, Lee JH, Wan R, King MT, Mughal MR, Okun E, Clarke K, Mattson MP, Veech RL, Neurobiol Aging 2013 34 1530 1539 10.1016/j.neurobiolaging.2012.11.023 23276384
6. Effect of reducing total fat intake on body weight: systematic review and meta-analysis of randomised controlled trials and cohort studies. Hooper L, Abdelhamid A, Moore HJ, Douthwaite W, Skeaff CM, Summerbell CD, BMJ 2012 345 7666 10.1136/bmj.e7666 23220130
7. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ, N Engl J Med 2008 359 229 241 10.1056/NEJMoa0708681 18635428
8. Four-year follow-up after two-year dietary interventions. Schwarzfuchs D, Golan R, Shai I, N Engl J Med 2012 367 1373 1374 10.1056/NEJMc1204792 23034044
9. Reduced or modified dietary fat for preventing cardiovascular disease. Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, Moore HJ, Davey Smith G, Cochrane Database Syst Rev 2012 5 D002137 22592684
10. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Volek JS, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, Kraemer WJ, Bibus DM, Fernandez ML, Feinman RD, Lipids 2009 44 297 309 10.1007/s11745-008-3274-2 19082851
11. Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. Greene AE, Todorova MT, Seyfried TN, J Neurochem 2003 86 529 537 10.1046/j.1471-4159.2003.01862.x 12859666
12. Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets. Mantis JG, Fritz CL, Marsh J, Heinrichs SC, Seyfried TN, Epilepsy Behav 2009 15 133 141 10.1016/j.yebeh.2009.02.038 19249385
13. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P, Br J Cancer 2003 89 1375 1382 10.1038/sj.bjc.6601269 14520474
14. Metabolic management of brain cancer. Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P, Biochim Biophys Acta 1807 2011 577 594
15. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. Maurer GD, Brucker DP, Bahr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP, Rieger J, BMC Cancer 2011 11 315 10.1186/1471-2407-11-315 21791085
16. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Veech RL, Prostaglandins Leukot Essent Fatty Acids 2004 70 309 319 10.1016/j.plefa.2003.09.007 14769489
17. Seizure resistance is dependent upon age and calorie restriction in rats fed a ketogenic diet. Bough KJ, Valiyil R, Han FT, Eagles DA, Epilepsy Res 1999 35 21 28 10.1016/S0920-1211(98)00125-9 10232791
18. Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies. Mantis JG, Centeno NA, Todorova MT, McGowan R, Seyfried TN, Nutr Metab (Lond) 2004 1 11 10.1186/1743-7075-1-11 15507133
19. Calorie restriction of a high-carbohydrate diet elevates the threshold of PTZ-induced seizures to values equal to those seen with a ketogenic diet. Eagles DA, Boyd SJ, Kotak A, Allan F, Epilepsy Res 2003 54 41 52 10.1016/S0920-1211(03)00041-X 12742595
20. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN, Nutr Metab (Lond) 2007 4 5 10.1186/1743-7075-4-5 17313687
21. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, Seyfried TN, Nutr Metab (Lond) 2010 7 33 10.1186/1743-7075-7-33 20412570
22. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Fine EJ, Segal-Isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, Bontempo AF, Negassa A, Sparano JA, Nutrition 2012 28 1028 1035 10.1016/j.nut.2012.05.001 22840388
23. Ketonuria after fasting may be related to the metabolic superiority. Joo NS, Lee DJ, Kim KM, Kim BT, Kim CW, Kim KN, Kim SM, J Korean Med Sci 2010 25 1771 1776 10.3346/jkms.2010.25.12.1771 21165293
24. Effect of 6-month adherence to a very low carbohydrate diet program. Westman EC, Yancy WS, Edman JS, Tomlin KF, Perkins CE, Am J Med 2002 113 30 36 12106620
25. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC, Ann Intern Med 2004 140 769 777 10.7326/0003-4819-140-10-200405180-00006 15148063
26. Long term effects of ketogenic diet in obese subjects with high cholesterol level. Dashti HM, Al-Zaid NS, Mathew TC, Al-Mousawi M, Talib H, Asfar SK, Behbahani AI, Mol Cell Biochem 2006 286 1 9 10.1007/s11010-005-9001-x 16652223
27. A pilot case study on the impact of a self-prescribed ketogenic diet on biochemical parameters and running performance in healthy and physically active individuals. Klement RJ, Frobel T, Albers T, Fikenzer S, Prinzhausen J, Kaemmerer U, Nutr Med 2013 1 10
28. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. Kwiterovich PO Jr, Vining EP, Pyzik P, Skolasky R Jr, Freeman JM, JAMA 2003 290 912 920 10.1001/jama.290.7.912 12928468
29. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Tendler D, Lin S, Yancy WS Jr, Mavropoulos J, Sylvestre P, Rockey DC, Westman EC, Dig Dis Sci 2007 52 589 593 10.1007/s10620-006-9433-5 17219068
30. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA, J Clin Endocrinol Metab 2003 88 1617 1623 10.1210/jc.2002-021480 12679447
31. Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. Meckling KA, O'Sullivan C, Saari D, J Clin Endocrinol Metab 2004 89 2717 2723 10.1210/jc.2003-031606 15181047
32. An isoenergetic very low carbohydrate diet improves serum HDL cholesterol and triacylglycerol concentrations, the total cholesterol to HDL cholesterol ratio and postprandial pipemic responses compared with a low fat diet in normal weight, normolipidemic women. Volek JS, Sharman MJ, Gomez AL, Scheett TP, Kraemer WJ, J Nutr 2003 133 2756 2761 12949361
33. How to use other drugs (steroids) and the ketogenic diet. De Vivo DC, Antiepileptic Drug Therapy in Pediatrics New York: Raven Press, Morselli PL, Pippenger CE, Penry JK, 1983 283 293
34. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. Gilbert DL, Pyzik PL, Freeman JM, J Child Neurol 2000 15 787 790 10.1177/088307380001501203 11198492
35. A high-fat, ketogenic diet induces a unique metabolic state in mice. Kennedy AR, Pissios P, Otu H, Roberson R, Xue B, Asakura K, Furukawa N, Marino FE, Liu FF, Kahn BB, Libermann TA, Maratos-Flier E, Am J Physiol Endocrinol Metab 2007 292 1724 E1739 10.1152/ajpendo.00717.2006 17299079
36. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. Badman MK, Kennedy AR, Adams AC, Pissios P, Maratos-Flier E, Am J Physiol Endocrinol Metab 2009 297 1197 E1204 10.1152/ajpendo.00357.2009 19738035
37. A comparison of fish oil, flaxseed oil and hempseed oil supplementation on selected parameters of cardiovascular health in healthy volunteers. Kaul N, Kreml R, Austria JA, Richard MN, Edel AL, Dibrov E, Hirono S, Zettler ME, Pierce GN, J Am Coll Nutr 2008 27 51 58 10.1080/07315724.2008.10719674 18460481
38. Fish oil supplementation alters circulating eicosanoid concentrations in young healthy men. Zulyniak MA, Perreault M, Gerling C, Spriet LL, Mutch DM, Metabolism 2013 62 1107 1113 10.1016/j.metabol.2013.02.004 23522836
39. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ, Am J Clin Nutr 2002 76 1007 1015 12399272
40. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ, Am J Clin Nutr 2000 71 1085 1094 10799369
41. Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ, Am J Clin Nutr 1999 70 817 825 10539741
42. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans. Dagnelie PC, Rietveld T, Swart GR, Stijnen T, van den Berg JW, Lipids 1994 29 41 45 10.1007/BF02537089 8139394
43. Dietary n-3 LCPUFA from fish oil but not alpha-linolenic acid-derived LCPUFA confers atheroprotection in mice. Degirolamo C, Kelley KL, Wilson MD, Rudel LL, J Lipid Res 2010 51 1897 1905 10.1194/jlr.M005058 20154006
44. Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice. Murali G, Milne GL, Webb CD, Stewart AB, McMillan RP, Lyle BC, Hulver MW, Saraswathi V, J Lipid Res 2012 53 2186 2197 10.1194/jlr.M029843 22847176
45. Beneficial effects of dietary fish-oil-derived monounsaturated fatty acids on metabolic syndrome risk factors and insulin resistance in mice. Yang ZH, Miyahara H, Mori T, Doisaki N, Hatanaka A, J Agric Food Chem 2011 59 7482 7489 10.1021/jf201496h 21627145
46. Dietary fish oil upregulates intestinal lipid metabolism and reduces body weight gain in C57BL/6J mice. Mori T, Kondo H, Hase T, Tokimitsu I, Murase T, J Nutr 2007 137 2629 2634 18029475
47. The adaptive effects of dietary fish and safflower oil on lipid and lipoprotein metabolism in perfused rat liver. Wong SH, Nestel PJ, Trimble RP, Storer GB, Illman RJ, Topping DL, Biochim Biophys Acta 1984 792 103 109 10.1016/0005-2760(84)90209-1 6696922
48. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Maalouf M, Rho JM, Mattson MP, Brain Res Rev 2009 59 293 315 10.1016/j.brainresrev.2008.09.002 18845187
49. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN, Carcinogenesis 2010 31 83 89 10.1093/carcin/bgp280 19969554
50. Caloric restriction: powerful protection for the aging heart and vasculature. Weiss EP, Fontana L, Am J Physiol Heart Circ Physiol 2011 301 1205 H1219 10.1152/ajpheart.00685.2011 21841020
51. Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice. Wu P, Shen Q, Dong S, Xu Z, Tsien JZ, Hu Y, Neurobiol Aging 2008 29 1502 1511 10.1016/j.neurobiolaging.2007.03.028 17499883
52. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Fontana L, Meyer TE, Klein S, Holloszy JO, Proc Natl Acad Sci U S A 2004 101 6659 6663 10.1073/pnas.0308291101 15096581
53. Caloric restriction in humans. Holloszy JO, Fontana L, Exp Gerontol 2007 42 709 712 10.1016/j.exger.2007.03.009 17482403
54. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Fontana L, Villareal DT, Weiss EP, Racette SB, Steger-May K, Klein S, Holloszy JO, Am J Physiol Endocrinol Metab 2007 293 197 E202 10.1152/ajpendo.00102.2007 17389710
55. Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, Pearson M, Nassar M, Telljohann R, Maudsley S, Carlson O, John S, Laub DR, Mattson MP, Free Radic Biol Med 2007 42 665 674 10.1016/j.freeradbiomed.2006.12.005 17291990
56. Hypocaloric diets and ketogenesis in the management of obese gestational diabetic women. Knopp RH, Magee MS, Raisys V, Benedetti T, Bonet B, J Am Coll Nutr 1991 10 649 667 10.1080/07315724.1991.10718184 1770194
57. Caloric restriction in C57BL/6J mice mimics therapeutic fasting in humans. Mahoney LB, Denny CA, Seyfried TN, Lipids Health Dis 2006 5 13 10.1186/1476-511X-5-13 16709251
58. Caloric restriction inhibits seizure susceptibility in epileptic EL mice by reducing blood glucose. Greene AE, Todorova MT, McGowan R, Seyfried TN, Epilepsia 2001 42 1371 1378 11879337
59. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Anson RM, Guo Z, de Cabo R, Iyun T, Rios M, Hagepanos A, Ingram DK, Lane MA, Mattson MP, Proc Natl Acad Sci U S A 2003 100 6216 6220 10.1073/pnas.1035720100 12724520
60. Anticonvulsant mechanisms of the ketogenic diet. Bough KJ, Rho JM, Epilepsia 2007 48 43 58 17241207
61. The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Cullingford TE, Prostaglandins Leukot Essent Fatty Acids 2004 70 253 264 10.1016/j.plefa.2003.09.008 14769484
62. Fish, n-3 polyunsaturated fatty acids, and cardiovascular disease. McEvoy C, Young IS, Woodside JV, Nutritional Health: Strategies for Disease Prevention New York: Humana Press, Temple NJ, Wilson T, Jacobs DRJ, 2012 ISBN Third
63. Fish oil rich diet in comparison to saturated fat rich diet offered protection against lipopolysaccharide-induced inflammation and insulin resistance in mice. Vijay-Kumar M, Vanegas SM, Patel N, Aitken JD, Ziegler TR, Ganji V, Nutr Metab (Lond) 2011 8 16 10.1186/1743-7075-8-16 21388548
64. Omega-3 fatty acids in inflammation and autoimmune diseases. Simopoulos AP, J Am Coll Nutr 2002 21 495 505 10.1080/07315724.2002.10719248 12480795
65. Omega-3 fatty acids and cardiovascular disease: The epidemiological evidence. Simopoulos AP, Environ Health Prev Med 2002 6 203 209 10.1007/BF02897971 21432336
66. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Calder PC, Am J Clin Nutr 2006 83 1505S 1519S 16841861
67. Enzymic determination of D(-)-beta-hydroxybutyric acid and acetoacetic acid in blood. Williamson DH, Mellanby J, Krebs HA, Biochem J 1962 82 90 96 14007241
68. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Baek RC, Martin DR, Cox NR, Seyfried TN, Lipids 2009 44 197 205 10.1007/s11745-008-3268-0 19034545
69. Analysis of brain lipids by high performance thin-layer chromatography and densitometry. Macala LJ, Yu RK, Ando S, J Lipid Res 1983 24 1243 1250 6631248
70. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Faul F, Erdfelder E, Lang AG, Buchner A, Behav Res Methods 2007 39 175 191 10.3758/BF03193146 17695343
71. Enhanced acceptance and metabolism of fats by rats fed a high-fat diet. Reed DR, Tordoff MG, Friedman MI, Am J Physiol 1991 261 1084 R1088 1951757
72. Methods of measuring insulin sensitivity. Trout KK, Homko C, Tkacs NC, Biol Res Nurs 2007 8 305 318 10.1177/1099800406298775 17456592
73. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Lansang MC, Williams GH, Carroll JS, Am J Hypertens 2001 14 51 53 10.1016/S0895-7061(00)01229-2 11206679
74. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y, Nat Med 2002 8 731 737 10.1038/nm724 12068289
75. Lang TA, Secic M, How to report Statistics in Medicine: Annotated Guidelines for Authors, Editors, and Reviewers Philadelphia: American College of Physicians 1997
76. Response of C57Bl/6 mice to a carbohydrate-free diet. Borghjid S, Feinman RD, Nutr Metab (Lond) 2012 9 69 10.1186/1743-7075-9-69 22838969
77. "A calorie is a calorie" violates the second law of thermodynamics. Feinman RD, Fine EJ, Nutr J 2004 3 9 10.1186/1475-2891-3-9 15282028
78. Pathways to obesity. Jequier E, Int J Obes Relat Metab Disord 2002 26 Suppl 2 12 S17 12174324
79. MacLean WC, Warwick P, Food and Agriculture Organization of the United Nations, Food energy: Methods of Analysis and Conversion Factors: Report of a Technical Workshop, Rome, 3-6 December 2002 Food and Agriculture Organization of the United Nations: Rome 2003
80. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol: Stockholm prospective study. Carlson LA, Bottiger LE, Lancet 1972 1 865 868 4111826
81. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Kannel WB, Castelli WP, Gordon T, Ann Intern Med 1979 90 85 91 10.7326/0003-4819-90-1-85 217290
82. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Hokanson JE, Austin MA, J Cardiovasc Risk 1996 3 213 219 10.1097/00043798-199604000-00014 8836866
83. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Ansar S, Koska J, Reaven PD, Cardiovasc Diabetol 2011 10 61 10.1186/1475-2840-10-61 21736746
84. Impaired glucose tolerance in rats fed low-carbohydrate, high-fat diets. Bielohuby M, Sisley S, Sandoval D, Herbach N, Zengin A, Fischereder M, Menhofer D, Stoehr BJ, Stemmer K, Wanke R, Tschöp MH, Seeley RJ, Bidlingmaier M, Am J Physiol Endocrinol Metab 2013 305 1059 E1070 10.1152/ajpendo.00208.2013 23982154
85. Long-term ketogenic diet causes glucose intolerance and reduced beta and alpha cell mass but no weight loss in mice. Ellenbroek JH, van Dijck L, Tons HA, Rabelink TJ, Carlotti F, Ballieux BE, de Koning EJ, Am J Physiol Endocrinol Metab 2014 306 552 E558 10.1152/ajpendo.00453.2013 24398402
86. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Beckman JA, Creager MA, Libby P, JAMA 2002 287 2570 2581 10.1001/jama.287.19.2570 12020339
87. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE, Circ Res 2007 100 769 781 10.1161/01.RES.0000259589.34348.74 17395883
88. Conversion of fatty acids to carbohydrate; application of isotopes to this problem and role of the Krebs cycle as a synthetic pathway. Weinman EO, Strisower EH, Chaikoff IL, Physiol Rev 1957 37 252 272 13441426
89. Plasma phosphatidylcholine/free cholesterol ratio as an indicator for atherosclerosis. Kuksis A, Roberts A, Thompson JS, Myher JJ, Geher K, Arteriosclerosis 1983 3 389 397 10.1161/01.ATV.3.4.389 6882292
90. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. Barber MN, Risis S, Yang C, Meikle PJ, Staples M, Febbraio MA, Bruce CR, PLoS One 2012 7 41456 10.1371/journal.pone.0041456 22848500
91. Plasma phosphatidylethanolamine-a better indicator in the predictability of atherosclerotic complications? Kunz F, Stummvoll W, Atherosclerosis 1971 13 413 425 10.1016/0021-9150(71)90083-9 5119241
92. Plasma sphingomyelin level as a risk factor for coronary artery disease. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR, Arterioscler Thromb Vasc Biol 2000 20 2614 2618 10.1161/01.ATV.20.12.2614 11116061
93. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K, Bickel C, Lackner KJ, Meyer J, Rupprecht HJ, Jiang XC, Nutr Metab (Lond) 2006 3 5 10.1186/1743-7075-3-5 16396678
94. Examining the role of insulin in the regulation of cardiovascular health. Salt IP, Future Cardiol 2013 9 39 52 10.2217/fca.12.77 23259474
95. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E, Science 2013 339 211 214 10.1126/science.1227166 23223453
96. Neuroprotective and disease-modifying effects of the ketogenic diet. Gasior M, Rogawski MA, Hartman AL, Behav Pharmacol 2006 17 431 439 10.1097/00008877-200609000-00009 16940764
97. The ketogenic diet in a pill: is this possible? Rho JM, Sankar R, Epilepsia 2008 49 Suppl 8 127 133 19049610
98. Ketones: metabolism's ugly duckling. VanItallie TB, Nufert TH, Nutr Rev 2003 61 327 341 10.1301/nr.2003.oct.327-341 14604265
99. Resistance to symptomatic insulin reactions after fasting. Drenick EJ, Alvarez LC, Tamasi GC, Brickman AS, J Clin Invest 1972 51 2757 2762 10.1172/JCI107095 5056667
100. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI, Diabetes 2006 55 924 928 10.2337/diabetes.55.04.06.db05-0985 16567512
101. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, Ruzickova J, Kopecky J, Diabetologia 2006 49 394 397 10.1007/s00125-005-0053-y 16397791
102. n-3 fatty acids and gene expression. Deckelbaum RJ, Worgall TS, Seo T, Am J Clin Nutr 2006 83 1520S 1525S 16841862
103. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Davidson MH, Am J Cardiol 2006 98 27i 33i 16919514
104. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans: a review. Lombardo YB, Chicco AG, J Nutr Biochem 2006 17 1 13 10.1016/j.jnutbio.2005.08.002 16214332
105. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM, Cell 2010 142 687 698 10.1016/j.cell.2010.07.041 20813258
106. Increase in fasting insulin and glucose over seven years with increasing weight and inactivity of young adults. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Folsom AR, Jacobs DR Jr, Wagenknecht LE, Winkhart SP, Yunis C, Hilner JE, Savage PJ, Smith DE, Flack JM, Am J Epidemiol 1996 144 235 246 10.1093/oxfordjournals.aje.a008918 8686692
107. The characteristics of impaired fasting glucose associated with obesity and dyslipidaemia in a Chinese population. Qian Y, Lin Y, Zhang T, Bai J, Chen F, Zhang Y, Luo S, Shen H, BMC Public Health 2010 10 139 10.1186/1471-2458-10- 139 20233452
108. Weight-loss diets-can you keep it off? Shai I, Stampfer MJ, Am J Clin Nutr 2008 88 1185 1186 18996849
109. The difference in the storage capacities for carbohydrate and for fat, and its implications in the regulation of body weight. Flatt JP, Ann N Y Acad Sci 1987 499 104 123 3300476
110. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. O'Keefe JH, Bell DS, Am J Cardiol 2007 100 899 904 10.1016/j.amjcard.2007.03.107 17719342
111. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Ford ES, Atherosclerosis 2004 173 309 314 15064107